Nexalin Technology, Inc.

NXL · Nasdaq · SIC 3845: Electromedical & Electrotherapeutic Apparatus
75
SEC Filings

Business Summary

PART I Overview Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devi...

Next Earnings

Q2 FY2026 — expected 2026-09-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNXLdiscussed_in_filing Data Center
topic_mentionNXLdiscussed_in_filing Cybersecurity
topic_mentionNXLdiscussed_in_filing Trusted Computing
topic_mentionNXLdiscussed_in_filing Blockchain & Crypto
topic_mentionNXLdiscussed_in_filing Semiconductor
topic_mentionNXLdiscussed_in_filing Supply Chain
topic_mentionNXLdiscussed_in_filing Regulation
topic_mentionNXLdiscussed_in_filing Enterprise
topic_mentionNXLdiscussed_in_filing Healthcare & Bio
topic_mentionNXLdiscussed_in_filing Platform & Ecosystem
topic_mentionNXLdiscussed_in_filing Sovereign & Government
topic_mentionNXLdiscussed_in_filing Data Center
topic_mentionNXLdiscussed_in_filing Cybersecurity
topic_mentionNXLdiscussed_in_filing Trusted Computing
topic_mentionNXLdiscussed_in_filing Blockchain & Crypto
topic_mentionNXLdiscussed_in_filing Semiconductor
topic_mentionNXLdiscussed_in_filing Supply Chain
topic_mentionNXLdiscussed_in_filing Regulation
topic_mentionNXLdiscussed_in_filing Enterprise
topic_mentionNXLdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-252025-12-310001829126-26-002673EDGAR68K words
2025-03-142024-12-310001829126-25-001794EDGAR—
2024-03-272023-12-310001829126-24-001935EDGAR—
2023-03-272022-12-310001829126-23-002259EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001829126-25-009159EDGAR22K words
2025-08-062025-06-300001829126-25-005851EDGAR—
2025-05-132025-03-310001829126-25-003612EDGAR—
2024-11-082024-09-300001829126-24-007369EDGAR—
2024-08-082024-06-300001829126-24-005306EDGAR—
2024-05-102024-03-310001829126-24-003241EDGAR—
2023-11-132023-09-300001829126-23-007325EDGAR—
2023-08-102023-06-300001829126-23-005281EDGAR—
2023-05-102023-03-310001829126-23-003245EDGAR—
2022-11-102022-09-300001829126-22-019147EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-250001829126-26-001634EDGAR1K words
2026-01-230001829126-26-000513EDGAR—
2025-12-050001829126-25-009755EDGAR—
2025-10-150001829126-25-008140EDGAR—
2025-09-220001829126-25-007572EDGAR—
2025-08-040001829126-25-005715EDGAR—
2025-07-210001829126-25-005224EDGAR—
2025-07-170001829126-25-005112EDGAR—
2025-06-090001829126-25-004343EDGAR—
2025-05-060001829126-25-003427EDGAR—

75 total filings indexed. 51 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ADMT — ADM TRONICS UNLIMITED, INC. AXGN — Axogen, Inc. BLFS — BIOLIFE SOLUTIONS INC CNMD — CONMED Corp CV — CapsoVision, Inc CBLL — Ceribell, Inc. EDAP — EDAP TMS SA ENDV — ENDONOVO THERAPEUTICS, INC.

Company Identity

CIK0001527352
TickerNXL
ExchangeNasdaq
SIC3845: Electromedical & Electrotherapeutic Apparatus
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 93b2bcacf9fd8514690e3506d34e36099709b6addf032ca6d6a987799b44787b
parent: e768c4bfc0f281165ab826c92e15eb2cbb0350a5315318c0c45b3ba41e18a2c1
content hash: cdd0c07c12e87420d49e1b60f7e33c25b13d2060f6d3313ac23c0d74992b23fd
signed: 2026-04-13T04:46:38.961Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf